Screen-detected prostate cancer and the insulin-like growth factor axis: Results of a population-based case-control study

International Journal of Cancer

Volumn 108, Issue 6, 2004, Pages 887-892

  Oliver, Steven E ^a   Gunnell, David ^b   Donovan, Jenny ^b   Peters, Tim J ^b   Persad, Raj ^c   Gillatt, David ^c   Pearce, Anya ^c   Neal, David E ^d   Hamdy, Freddie C ^e   Holly, Jeff ^c  

^a UNIVERSITY OF YORK   (United Kingdom)

^b UNIVERSITY OF BRISTOL   (United Kingdom)

^c BRISTOL ROYAL INFIRMARY   (United Kingdom)

^d UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^e UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

Case control study; Insulin like growth factor axis; Prostatic neoplasms

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; SOMATOMEDIN; SOMATOMEDIN B; SOMATOMEDIN BINDING PROTEIN 1; SOMATOMEDIN BINDING PROTEIN 2; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C;

ADULT; ADVANCED CANCER; AGED; ALCOHOL CONSUMPTION; ARTICLE; CANCER RISK; CANCER SCREENING; CIGARETTE SMOKING; CONTROLLED STUDY; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; POPULATION RESEARCH; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROTEIN BLOOD LEVEL; RISK ASSESSMENT; SMOKING HABIT; STATISTICAL ANALYSIS;

AGED; CASE-CONTROL STUDIES; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MALE; MASS SCREENING; MIDDLE AGED; ODDS RATIO; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RISK; TIME FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 9144269886     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.11631     Document Type: Article

References (34)

1. Parkin DM, Whelan SL, Ferlay J, Raymond L, Young J. Cancer in five continents. vol. 7. Lyon: IARC, 1997.
2. Minino AM, Arias E, Kochanek KD, Murphy SL, Smith BL. Deaths: final data for 2000-national vital statistics reports. Hyattsville, MD: National Center for Health Statistics, 2002.
3. Chan JM, Stampfer MJ, Giovannucci E, et al. Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science 1998;279:563-6.
4. Hankinson SE, Willett WC, Colditz GA, et al. Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet 1998;351:1393-6.
5. Toniolo P, Bruning PF, Akhmedkhanov A, et al. Serum insulin-like growth factor-I and breast cancer. Int J Cancer 2000;88:828-32.
6. Ma J, Pollak MN, Giovannucci E, et al. Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3. J Natl Cancer Inst 1999;91:620-5.
7. Giovannucci E, Pollak M, Platz EA. et al. Insulin-like growth factor I (IGF-I), IGF-binding protein-3 and the risk of colorectal adenoma and cancer in the nurses' health study. Growth Hormone IGF Res 2000;10:S30-1.
8. Yu H, Roban T. Role of the insulin-like growth factor family in cancer development and progression. J Natl Cancer Inst 2000;92:1472-89.
9. Grimberg A, Cohen P. Role of insulin-like growth factors and their binding proteins in growth control and carcinogenesis. J Cell Physiol 2000;183:1-9.
10. Stattin P, Bylund A, Rinaldi S, et al. Plasma insulin-like growth factor-I, insulin-like growth factor-binding proteins, and prostate cancer risk: a prospective study. J Natl Cancer Inst 2000;92:1910-7.
11. Harman SM. Metter EJ, Blackman MR, Landis PK, Carter HB, Baltimore Longitudinal Study on Aging. Serum levels of insulin-like growth factor I (IGF-I), IGF-II, IGF-binding protein-3, and prostate-specific antigen as predictors of clinical prostate cancer. J Clin Endocrinol Metab 2000;85:4258-65.
12. Chan JM, Stampfer MJ, Ma J, et al. Insulin-like growth factor-I (IGF-I) and IGF binding protein-3 as predictors of advanced-stage prostate cancer. J Natl Cancer Inst 2002;94:1099-106.
13. Mantzoros CS, Tzonou A, Signorello LB, et al. Insulin-like growth factor I in relation to prostate cancer and benign prostatic hyperplasia. Br J Cancer 1997;76:1115-8.
14. Wolk A, Mantzoros CS, Andersson SO, et al. Insulin-like growth factor I and prostate cancer risk: a population-based, case-control study. J Natl Cancer Inst 1998;90:911-5.
15. Chokkalingam AP, Pollak M, Fillmore C-M, et al. Insulin-like growth factors and prostate cancer: a population-based case-control study in China. Cancer Epidemiol Biomark Prevent 2001;10:421-7.
16. Hankey BF, Feuer EJ, Clegg LX, et al. Cancer surveillance series: interpreting trends in prostate cancer-part I: Evidence of the effects of screening in recent prostate cancer incidence, mortality, and survival rates. J Natl Cancer Inst 1999;91:1017-24.
17. Donovan J, Mills N, Smith M, et al. Improving design and conduct of randomised trials by embedding them in qualitative research: PROTECT (Prostate Testing for Cancer and Treatment) study. Br Med J 2002;325:766-9.
18. Gleason DF. Histologic grading of prostate cancer: a perspective. Hum Pathol 1992;23:273-9.
19. Schroeder FH, Hermanek L, Denis L, Fair MK, Gospodarowicz MH, Pavone-Macaluso M. TNM classification of prostate cancer. Prostate 1992;4(Suppl):129-38.
20. Cheetham TD, Holly JM, Baxter RC, et al. The effects of recombinant human IGF-I administration on concentrations of acid labile subunit, IGF binding protein-3, IGF-I, IGF-II and proteolysis of IGF binding protein-3 in adolescents with insulin-dependent diabetes mellitus. J Endocrinol 1998;157:81-7.
21. Baxter RC. Circulating binding proteins for the insulin-like growth factors. Trends Endocrinol Metab 1993;4:91-6.
22. Lacey JV Jr, Hsing AW, Fillmore C-M, Hoffman S, Helzlsouer KJ, Comstock GW. Null association between insulin-like growth factors, insulin-like growth factor-binding proteins, and prostate cancer in a prospective study. Cancer Epidemiol Biomark Prevent 2001;10:1101-2.
23. Manousos O, Souglakos J, Bosetti C. et al. IGF-I and IGF-II in relation to colorectal cancer. Int J Cancer 1999;83:15-7.
24. Probst-Hensch NM, Yuan JM, Stanczyk FZ, Gao YT, Ross RK, Yu MC. IGF-1, IGF-2 and IGFBP-3 in prediagnostic serum: association with colorectal cancer in a cohort of Chinese men in Shanghai. Br J Cancer 2001;85:1695-9.
25. Renehan AG, Painter JE, O'Halloran D, et al. Circulating insulin-like growth factor II and colorectal adenomas. J Clin Endocrinol Metab 2000;85:3402-8.
26. Kanety H, Madjar Y, Dagan Y. et al. Serum insulin-like growth factor-binding protein-2 (IGFBP-2) is increased and IGFBP-3 is decreased in patients with prostate cancer: correlation with serum prostate-specific antigen. J Clin Endocrinol Metab 1993;77:229-33.
27. Cohen P, Peehl DM, Stamey TA, Wilson KF, Clemmons DR, Rosenfeld RG. Elevated levels of insulin-like growth factor-binding protein-2 in the serum of prostate cancer patients. J Clin Endocrinol Metab 1993;76:1031-5.
28. Goodman-Gruen D, Barrett-Connor E. Epidemiology of insulin-like growth factor-I in elderly men and women: the Rancho Bernardo Study. Am J Epidemiol 1997;145:970-6.
29. Kaklamani VG, Linos A, Kaklamani E, Markaki I, Mantzoros C. Age, sex, and smoking are predictors of circulating insulin-like growth factor I and insulin-like growth factor-binding protein 3, J Clin Oncol 1999;17:813-7.
30. Signorello LB, Kuper H, Lagiou P, et al. Lifestyle factors and insulin-like growth factor I levels among elderly men. Eur J Cancer Prevent 2000;9:173-8.
31. Landin-Wilhelmsen K, Wilhelmsen L, Lappas G, et al. Serum insulin-like growth factor I in a random population sample of men and women: relation to age, sex, smoking habits, coffee consumption and physical activity, blood pressure and concentrations of plasma lipids, fibrinogen, parathyroid hormone and osteocalcin. Clin Endocrinol 1994;41:351-7.
32. Crown AL, Cottle K, Lightman SL. et al. What is the role of the insulin-like growth factor system in the pathophysiology of cancer cachexia, and how is it regulated? Clin Endocrinol 2002;56:723-33.
33. Yao SL, Lu-Yao G. Understanding and appreciating overdiagnosis in the PSA era. J Natl Cancer Inst 2002;94:958-60.
34. Smith GD, Gunnell D, Holly J. Cancer and insulin-like growth factor-I: a potential mechanism linking the environment with cancer risk. Br Med J 2000:321:847-8.